BioAffinity Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . bioAffinity Technologies
BIAF Stock  USD 1.25  0.03  2.46%   
BioAffinity Technologies' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing BioAffinity Technologies' valuation are provided below:
Gross Profit
1.9 M
Profit Margin
(2.17)
Market Capitalization
5.8 M
Enterprise Value Revenue
1.1383
Revenue
6.8 M
There are over one hundred nineteen available fundamental signals for bioAffinity Technologies, which can be analyzed over time and compared to other ratios. Active traders should verify all of bioAffinity Technologies prevailing fundamental drivers against the trend between 2010 and 2026 to make sure the company can sustain itself down the road.

BioAffinity Technologies Total Revenue

11.3 Million

Check BioAffinity Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioAffinity Technologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 731.3 K, Interest Expense of 79.1 K or Gross Profit of 4.1 M, as well as many indicators such as Price To Sales Ratio of 1.29, Dividend Yield of 0.0 or PTB Ratio of 4.01. BioAffinity financial statements analysis is a perfect complement when working with BioAffinity Technologies Valuation or Volatility modules.
  
Build AI portfolio with BioAffinity Stock
Check out the analysis of BioAffinity Technologies Correlation against competitors.
For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies guide.

BioAffinity Technologies Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.3 M7.5 M2.8 M
Slightly volatile
Short and Long Term Debt Total1.3 M1.4 M4 M
Pretty Stable
Other Current Liabilities1.1 M1.6 M836.8 K
Slightly volatile
Total Current Liabilities4.7 M2.8 M5 M
Very volatile
Property Plant And Equipment Net2 M1.9 M467.5 K
Slightly volatile
Accounts Payable1.2 M1.1 M336.5 K
Slightly volatile
Cash1.2 M1.3 M1.5 M
Slightly volatile
Non Current Assets Total4.6 M4.4 M1 M
Slightly volatile
Non Currrent Assets Other15.1 K22.6 K13.7 K
Slightly volatile
Cash And Short Term Investments1.2 M1.3 M1.5 M
Slightly volatile
Net Receivables1.4 M1.3 M274.4 K
Slightly volatile
Common Stock Shares Outstanding290.3 K465 K267.8 K
Slightly volatile
Liabilities And Stockholders Equity5.3 M7.5 M2.8 M
Slightly volatile
Other Current Assets255.8 K486.4 K145.6 K
Slightly volatile
Other Stockholder Equity33 M64.6 M19.9 M
Slightly volatile
Total Liabilities6.1 M3.5 M5.7 M
Pretty Stable
Total Current Assets3.8 M3.1 M2 M
Slightly volatile
Short Term Debt593.8 K625 K3.8 M
Slightly volatile
Common Stock128.7 K122.6 K41.6 K
Slightly volatile
Other Assets11.2 K9.4 K15 K
Slightly volatile
Long Term Debt17.3 K18.2 K49.7 K
Slightly volatile
Non Current Liabilities Total689.8 K726.1 K3.1 M
Slightly volatile
Inventory24.3 K24.8 K28.5 K
Very volatile
Property Plant And Equipment Gross2.6 M2.5 M779.5 K
Slightly volatile
Short and Long Term Debt146.8 K154.5 K7.2 M
Slightly volatile
Capital Stock128.7 K122.6 K41.6 K
Slightly volatile
Property Plant Equipment5.6 K4.2 K7.8 K
Slightly volatile
Deferred Long Term Liabilities6.4 K7.1 K7.8 K
Slightly volatile
Current Deferred Revenue23 K22 K31.3 K
Slightly volatile
Intangible Assets643.4 K697.6 K810.9 K
Slightly volatile

BioAffinity Technologies Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization731.3 K696.5 K160.2 K
Slightly volatile
Interest Expense79.1 K83.2 K374 K
Pretty Stable
Other Operating Expenses22.1 M21.1 M6.6 M
Slightly volatile
Research Development1.8 M2.1 M1.8 M
Pretty Stable
Cost Of Revenue7.2 M6.9 M1.3 M
Slightly volatile
Total Operating Expenses14.9 M14.2 M5.3 M
Slightly volatile
Income Tax Expense7.9 K13.4 K5.5 K
Slightly volatile
Tax Provision8.3 K13.4 K5.1 K
Slightly volatile
Interest Income19.2 K20.3 K15.6 K
Slightly volatile
Selling General Administrative12 M11.4 M3.2 M
Slightly volatile
Reconciled Depreciation731.3 K696.5 K141.2 K
Slightly volatile

BioAffinity Technologies Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Change In Working Capital196.3 K206.7 K349 K
Very volatile
Begin Period Cash Flow3.1 M3.2 M1.8 M
Slightly volatile
Depreciation731.3 K696.5 K160.2 K
Slightly volatile
End Period Cash Flow1.2 M1.3 M1.5 M
Slightly volatile
Stock Based Compensation1.2 M1.1 M435.1 K
Slightly volatile
Change To Operating Activities543.6 K682.9 K467.2 K
Slightly volatile
Change To Netincome3.1 M2.8 M4 M
Slightly volatile
Change To Liabilities50.8 K35.1 K71.2 K
Slightly volatile
Dividends Paid148166182
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.291.361.1 K
Slightly volatile
Days Sales Outstanding48.5251.08625
Slightly volatile
Average Payables242.7 K427.4 K224.5 K
Slightly volatile
Stock Based Compensation To Revenue0.120.105739.6171
Slightly volatile
Capex To Depreciation0.140.152.7461
Pretty Stable
Inventory Turnover20519542.3253
Slightly volatile
Days Of Inventory On Hand1.841.94811
Pretty Stable
Payables Turnover5.735.451.4207
Slightly volatile
Research And Ddevelopement To Revenue0.210.22243
Slightly volatile
Capex To Revenue0.00920.009735.0272
Slightly volatile
Cash Per Share2.342.467.2183
Pretty Stable
Days Payables Outstanding51.554.2117.6 K
Pretty Stable
Income Quality0.460.720.6706
Slightly volatile
Intangibles To Total Assets0.240.30.2756
Pretty Stable
Current Ratio0.740.780.9469
Slightly volatile
Receivables Turnover7.777.41.9094
Slightly volatile
Capex Per Share0.290.180.2443
Slightly volatile
Average Receivables388.5 K370 K97.6 K
Slightly volatile
Revenue Per Share21.8820.844.4102
Slightly volatile
Interest Debt Per Share4.314.5317.7204
Pretty Stable
Debt To Assets0.250.278.1406
Very volatile
Operating Cycle50.3653.01920
Pretty Stable
Days Of Payables Outstanding51.554.2117.6 K
Pretty Stable
Ebt Per Ebit1.971.161.3827
Slightly volatile
Quick Ratio0.730.770.9442
Slightly volatile
Net Income Per E B T0.80.90.9832
Slightly volatile
Cash Ratio0.30.320.7999
Pretty Stable
Days Of Inventory Outstanding1.841.94811
Pretty Stable
Days Of Sales Outstanding48.5251.08625
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.810.910.9935
Slightly volatile
Fixed Asset Turnover5.465.21.0589
Slightly volatile
Debt Ratio0.250.278.1406
Very volatile
Price Sales Ratio1.291.361.1 K
Slightly volatile
Asset Turnover1.361.290.2588
Slightly volatile
Gross Profit Margin0.580.420.7888
Slightly volatile

BioAffinity Technologies Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap8.8 M9.9 M10.8 M
Slightly volatile
Enterprise Value9.1 M10.3 M11.2 M
Slightly volatile

BioAffinity Fundamental Market Drivers

BioAffinity Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About BioAffinity Technologies Financial Statements

BioAffinity Technologies stakeholders use historical fundamental indicators, such as BioAffinity Technologies' revenue or net income, to determine how well the company is positioned to perform in the future. Although BioAffinity Technologies investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioAffinity Technologies' assets and liabilities are reflected in the revenues and expenses on BioAffinity Technologies' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in bioAffinity Technologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue22 K23 K
Cost Of Revenue6.9 M7.2 M
Total Revenue10.8 M11.3 M
Stock Based Compensation To Revenue 0.11  0.12 
Research And Ddevelopement To Revenue 0.22  0.21 
Capex To Revenue 0.01  0.01 
Revenue Per Share 20.84  21.88 
Ebit Per Revenue(0.86)(0.90)

Currently Active Assets on Macroaxis

JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc
WMTWalmart Common Stock
QYLDGlobal X NASDAQ
When determining whether bioAffinity Technologies is a strong investment it is important to analyze BioAffinity Technologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BioAffinity Technologies' future performance. For an informed investment choice regarding BioAffinity Stock, refer to the following important reports:
How To Invest In BioAffinity
Details
Is BioAffinity Stock a good investment?
Details
What is BioAffinity Technologies' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of BioAffinity Technologies Correlation against competitors.
For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(13.83)
Revenue Per Share
9.324
Quarterly Revenue Growth
(0.39)
Return On Assets
(0.72)
Return On Equity
(2.45)
The market value of bioAffinity Technologies is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies' value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies' market value can be influenced by many factors that don't directly affect BioAffinity Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between BioAffinity Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY